List of Excipients in Branded Drug TAZVERIK

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Epizyme Inc	TAZVERIK	tazemetostat	72607-100	FERRIC OXIDE RED	2035-12-19
Epizyme Inc	TAZVERIK	tazemetostat	72607-100	HYDROXYPROPYL CELLULOSE	2035-12-19
Epizyme Inc	TAZVERIK	tazemetostat	72607-100	HYPROMELLOSE	2035-12-19
Epizyme Inc	TAZVERIK	tazemetostat	72607-100	LACTOSE MONOHYDRATE	2035-12-19

Tazverik Excipient Strategy and Commercial Opportunities for Tazemetostat

Last updated: August 9, 2026

Tazverik (tazemetostat) is an oral EZH2 inhibitor marketed by Ipsen after its acquisition of Epizyme. Its commercial formulation is a 200 mg film-coated tablet administered at 800 mg twice daily, creating a high tablet burden of eight tablets per day. The strongest excipient opportunities are improved swallowability, reduced lactose exposure, pediatric and geriatric dosage forms, global excipient harmonization, and manufacturing-cost reduction without changing bioavailability.

The formulation strategy is constrained by a relatively high daily dose, chronic oncology use, accelerated-approval indications, and the need to preserve bioequivalence for future line extensions or generic competition.

What is Tazverik and how is it administered?

Tazverik contains tazemetostat hydrobromide, an oral small-molecule inhibitor of enhancer of zeste homolog 2, or EZH2. EZH2 is the catalytic subunit of the polycomb repressive complex 2 and mediates histone H3 lysine 27 methylation.

The FDA-approved indications are:

Indication	Patient population	Approved dose	FDA status
Epithelioid sarcoma	Adults and adolescents age 16 years and older with metastatic or locally advanced disease not eligible for complete resection	800 mg orally twice daily	Accelerated approval
Follicular lymphoma	Adults with relapsed or refractory disease after at least two prior systemic therapies	800 mg orally twice daily	Accelerated approval
Follicular lymphoma with EZH2 mutation	Adults with relapsed or refractory disease after at least two prior systemic therapies	800 mg orally twice daily	Accelerated approval
Follicular lymphoma without satisfactory alternative treatment options	Adults with relapsed or refractory disease	800 mg orally twice daily	Accelerated approval

Patients take four 200 mg tablets per dose, normally eight tablets daily. The label permits administration with or without food, which reduces food-effect complexity and supports outpatient use (U.S. Food and Drug Administration [FDA], 2024).

What excipients are used in the Tazverik tablet?

The commercial Tazverik tablet uses conventional oral solid-dose excipients. The FDA prescribing information identifies the following inactive ingredients:

Component	Likely functional role
Lactose monohydrate	Diluent and compressibility aid
Microcrystalline cellulose	Filler, binder, and tablet-strength contributor
Croscarmellose sodium	Superdisintegrant
Colloidal silicon dioxide	Glidant and flow-control agent
Magnesium stearate	Lubricant
Polyvinyl alcohol	Film-coating polymer
Titanium dioxide	Opacifier and colorant
Talc	Coating aid and anti-tacking agent
Polyethylene glycol	Plasticizer in the film coat

The label identifies lactose monohydrate as an inactive ingredient. That fact has commercial relevance for patients with lactose intolerance, excipient-sensitive patients, and markets where lactose declaration and patient-information requirements affect product positioning.

The formulation is a conventional immediate-release film-coated tablet rather than a modified-release, lipid-based, multiparticulate, or controlled-delivery product. That simplifies manufacturing and supports generic development, but it leaves room for differentiated dosage-form strategies.

What are the main excipient constraints in Tazverik development?

High daily tablet burden

The 800 mg twice-daily regimen requires four 200 mg tablets at each administration. A replacement formulation must preserve dose flexibility while improving swallowability and adherence.

A single 800 mg tablet could reduce pill burden, but tablet size, mechanical strength, dissolution, and dose uniformity would be significant constraints. A 400 mg tablet could reduce daily tablet count from eight to four and may be more practical than a single 800 mg unit.

Lactose exposure

Lactose is a low-cost, widely accepted diluent, but it can create barriers in patients with lactose intolerance and in markets requiring prominent excipient disclosure. A lactose-free formulation could use mannitol, anhydrous dibasic calcium phosphate, pregelatinized starch, silicified microcrystalline cellulose, or a combination of these excipients.

Each substitute affects powder flow, compaction, hygroscopicity, dissolution, tablet weight, and stability. Mannitol could support an orally disintegrating tablet, but its cooling sensation and potential friability must be controlled. Dibasic calcium phosphate could improve tablet hardness but may alter dissolution and is less suitable for every formulation platform.

Chronic oncology treatment

Tazverik treatment can continue until disease progression or unacceptable toxicity. Long-term use increases the commercial value of excipient changes that improve gastrointestinal tolerability, swallowing, packaging convenience, and adherence.

The main tolerability-related adverse reactions in the FDA label include nausea, decreased appetite, vomiting, constipation, abdominal pain, and diarrhea. An excipient change cannot be marketed as reducing these adverse reactions without clinical evidence. It can, however, target administration burden and patient acceptability.

High-dose solid-state requirements

Tazemetostat hydrobromide must maintain consistent particle properties, polymorphic form, assay, content uniformity, and dissolution. Excipient substitutions can alter wetting and drug release even when the active pharmaceutical ingredient and tablet strength remain unchanged.

For a differentiated product, the most defensible development path is a formulation with a measurable performance advantage, such as:

• faster disintegration without impaired stability;
• lower tablet mass at the same dose;
• improved swallowability;
• lower lactose content;
• reduced friability;
• better humidity resistance; or
• a pediatric-appropriate dosage form.

Which excipient strategies offer the strongest commercial opportunities?

Lactose-free immediate-release tablets

A lactose-free version is the most straightforward lifecycle-management opportunity. The product could preserve the current 200 mg strength and 800 mg twice-daily regimen while replacing lactose with a directly compressible filler system.

Commercial advantages include broader patient acceptability, simplified positioning for lactose-sensitive patients, and a potential formulation patent if the excipient ratio and performance characteristics are specific and non-obvious.

The commercial limitation is substitution risk. A generic manufacturer could often develop a Q1/Q2-different tablet using another standard filler without infringing a narrow excipient patent.

Higher-strength tablets

A 400 mg tablet could cut daily tablet count in half. The formulation would need to demonstrate comparable exposure and dissolution to the 200 mg reference product. A higher-strength product could be valuable for adherence, specialty-pharmacy dispensing, and patient support programs.

An 800 mg tablet would have greater commercial appeal but faces practical limits involving size, compression force, tablet friability, and swallowability. A multilayer or tablet-in-tablet design could address some constraints, but it would increase manufacturing complexity and regulatory risk.

Orally disintegrating tablets

An orally disintegrating tablet, or ODT, could target patients with dysphagia, advanced cancer, or difficulty swallowing multiple tablets. Mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and flavoring systems are common development tools.

Tazemetostat’s bitter taste, high dose, and need for four tablets per administration make an ODT challenging. An ODT may be commercially viable at 200 mg, but the patient would still require multiple units unless a higher-strength ODT is developed. Taste masking, moisture protection, friability, and rapid disintegration would be central patent and regulatory issues.

Oral granules or sprinkle formulation

A granule or sprinkle formulation could support patients unable to swallow tablets and may create a pediatric extension opportunity. The product would need to address dose uniformity, powder segregation, taste, stability, and administration with soft food or liquid.

This strategy has higher formulation and regulatory complexity than a lactose-free tablet but could create a more differentiated product profile. It may also support hospital and specialty-care use where administration flexibility has economic value.

Pediatric formulation

The current label includes patients age 16 years and older for epithelioid sarcoma. Pediatric oncology development could create demand for lower-strength tablets, dispersible tablets, granules, or an oral suspension.

A pediatric formulation would need age-appropriate dosing, palatability, dose measurement, excipient safety, and a pediatric pharmacokinetic bridge. Preservatives, sweeteners, polyols, and flavoring agents would require careful selection because repeated dosing may increase gastrointestinal burden.

Global excipient harmonization

A single global formulation can reduce supply-chain complexity, but some excipients face regional restrictions or labeling sensitivities. A global strategy should evaluate:

• lactose declaration requirements;
• titanium dioxide restrictions and market-specific labeling;
• talc quality and elemental impurity controls;
• polyethylene glycol grade and peroxide limits;
• nitrosamine risk from excipient and packaging interactions;
• residual solvents;
• elemental impurities under ICH Q3D; and
• pharmacopoeial differences among USP, Ph. Eur., JP, and other standards.

Replacing titanium dioxide or talc in the film coat may have value in certain jurisdictions, but color and opacity changes can create product-recognition and stability issues.

How should a Tazverik excipient patent strategy be structured?

A formulation patent should avoid relying only on the presence of a conventional excipient. Stronger claims generally connect excipient selection to a measurable technical result.

Potential claim themes include:

1. A tazemetostat tablet containing a defined ratio of active ingredient, filler, disintegrant, glidant, and lubricant.
2. A lactose-free formulation with specified dissolution limits.
3. A high-strength tablet meeting defined hardness, friability, and disintegration parameters.
4. An ODT with a specified disintegration time and taste-masking system.
5. A granule or sprinkle formulation with dose-uniformity and stability limits.
6. A formulation with reduced hygroscopicity or improved storage stability.
7. A manufacturing process using a specified granulation, milling, compression, or coating sequence.
8. A package-formulation combination that controls moisture or oxygen exposure.

Process patents can be more difficult to enforce against an ANDA applicant because manufacturing details may not be publicly disclosed before launch. Composition and performance claims are generally more visible and commercially useful, although they must be drafted to avoid easy design-around.

What patents protect Tazverik and when does exclusivity end?

Tazverik has composition-of-matter and regulatory exclusivity considerations associated with tazemetostat. The exact patent and Orange Book position must be evaluated against the current FDA Orange Book and U.S. Patent and Trademark Office records because listed patents, pediatric extensions, terminal disclaimers, and litigation outcomes can affect the operative date.

The principal exclusivity framework is:

Protection	Commercial relevance
Composition-of-matter patent	Primary barrier to generic entry
Formulation patent	Protects specific dosage forms or excipient systems
Method-of-use patent	Can delay or complicate approval for selected indications
Orphan-drug exclusivity	Protects the approved orphan indication from the same drug for seven years, subject to statutory exceptions
Pediatric exclusivity	Can add six months to qualifying listed protections
New clinical investigation exclusivity	May apply to certain qualifying approvals or supplements

Tazverik’s indications were granted accelerated approval, so postmarketing requirements and confirmatory evidence remain relevant to the regulatory profile. Orphan-drug exclusivity is indication-specific and does not necessarily block every generic or every use of the active ingredient.

What is the Orange Book and Paragraph IV risk for Tazverik?

Tazverik is an FDA-approved small-molecule tablet, so an ANDA pathway is the primary generic route. A generic applicant may file a Paragraph IV certification against listed patents, asserting that the patents are invalid, unenforceable, or not infringed.

The principal generic entry scenarios are:

• Paragraph III filing: the applicant accepts listed patent protection and delays launch until the relevant date.
• Paragraph IV filing: the applicant challenges one or more listed patents and may trigger patent litigation.
• Section viii statement: the applicant seeks approval for a label that omits a patented method of use, where legally and clinically feasible.
• Post-expiration filing: the applicant waits for listed patent protection to expire.

For an immediate-release tablet, the generic product would likely seek a biowaiver only if applicable under FDA requirements. Otherwise, comparative pharmacokinetic studies would be expected. The applicant would also need to address active-ingredient sameness, strength, dosage form, route, inactive ingredients, dissolution, impurities, and labeling.

A conventional excipient profile makes generic development technically accessible. Differentiated formulation patents could delay competition only if they cover required aspects of the approved product or support enforceable method-of-use restrictions.

Which companies are challenging Tazverik exclusivity?

Publicly available commercial information identifies generic competition as a future risk rather than an established market event. Tazverik’s competitive pressure also comes from alternative therapies in follicular lymphoma and epithelioid sarcoma, including other targeted agents, immunotherapies, chemotherapy, and clinical trials.

No biosimilar pathway applies because tazemetostat is a chemically synthesized small molecule, not a biologic. The relevant competitive pathways are ANDA generics, branded EZH2 or epigenetic competitors, and off-label use of other oncology agents.

How does Tazverik compare with competing oral oncology products?

Tazverik’s formulation opportunity is different from that of many targeted oncology drugs.

Factor	Tazverik	Commercial implication
Dosage form	Immediate-release film-coated tablet	Supports conventional generic development
Dose burden	800 mg twice daily	Strong case for higher-strength or easier-to-swallow products
Food requirement	With or without food	Improves patient convenience
Active ingredient	Small molecule	ANDA competition, not biosimilar competition
Treatment setting	Relapsed or refractory oncology	Specialty pharmacy and adherence support are important
Excipient profile	Includes lactose and standard coating agents	Opportunity for lactose-free or regionally optimized versions
Regulatory status	Accelerated approvals	Confirmatory evidence and indication durability affect lifecycle value

Compared with lower-dose targeted therapies, Tazverik has a more pronounced tablet-burden problem. Compared with liquid oncology products, it has simpler logistics, lower packaging complexity, and lower microbial-control risk.

What commercial opportunities exist for manufacturers and licensees?

The most attractive opportunities are likely to be lifecycle products rather than commodity excipient supply alone.

Formulation technology licensors

Specialty formulation companies could offer:

• high-load direct-compression platforms;
• taste-masked granules;
• ODT technology;
• low-lactose or lactose-free filler systems;
• moisture-protective coating systems; and
• pediatric oral dosage platforms.

A licensee would have stronger negotiating leverage with a formulation that produces clinical or operational value rather than simply replacing one standard excipient with another.

Excipient suppliers

Excipient suppliers can target the product through:

• co-processed excipients that improve flow and compactability;
• low-moisture grades;
• directly compressible mannitol or microcrystalline cellulose;
• disintegrants optimized for high-dose tablets;
• titanium-dioxide-free coating systems; and
• low-peroxide polyethylene glycol grades.

The commercial opportunity is greatest if the excipient enables a smaller tablet, faster disintegration, fewer manufacturing steps, or improved stability.

Contract manufacturers

Contract development and manufacturing organizations can compete through a complete lifecycle package: formulation screening, scale-up, process validation, stability, regulatory support, and commercial supply. A high-strength or pediatric presentation would likely require more development work than the current tablet.

What is the likely generic launch risk?

The generic risk is moderate to high after core patent protection ends because Tazverik is a conventional immediate-release small-molecule tablet with no biosimilar complexity and no evident delivery-system barrier.

Risk factors that support generic entry include:

• standard tablet technology;
• oral administration;
• no food restriction;
• established clinical dose;
• conventional inactive ingredients; and
• availability of multiple excipient design options.

Factors that can delay or complicate entry include:

• remaining composition-of-matter patents;
• listed method-of-use patents;
• orphan-drug exclusivity for specific indications;
• patent litigation following a Paragraph IV filing;
• complex labeling carve-outs; and
• postmarketing safety or confirmatory-trial developments.

Key Takeaways

• Tazverik is an 800 mg twice-daily tazemetostat tablet requiring eight 200 mg tablets per day.
• The current formulation uses standard excipients, including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and conventional film-coating materials.
• The clearest excipient opportunity is a lactose-free or lower-tablet-burden formulation.
• A 400 mg tablet is more technically plausible than a single 800 mg tablet.
• ODT, granule, sprinkle, and pediatric formulations offer greater differentiation but carry higher development and regulatory costs.
• Tazemetostat is a small molecule, so generic competition will proceed through ANDA and Paragraph IV mechanisms rather than biosimilar pathways.
• Formulation patents should claim composition, performance, and manufacturing features tied to measurable technical advantages.
• Generic risk is structurally meaningful because the product is an immediate-release conventional tablet.
• Regulatory exclusivity remains indication-specific, particularly because the approved indications received accelerated approval.
• Excipient suppliers and formulation licensors should focus on measurable improvements in tablet size, disintegration, stability, palatability, or administration flexibility.

FAQs About Tazverik Excipient and Formulation Opportunities

Can Tazverik be reformulated without lactose?

Yes. Lactose can potentially be replaced with mannitol, silicified microcrystalline cellulose, pregelatinized starch, dibasic calcium phosphate, or another compatible filler system. The replacement must preserve dissolution, stability, content uniformity, and bioequivalence.

Is a liquid Tazverik formulation commercially attractive?

A liquid or suspension could serve patients with dysphagia and pediatric populations, but the high daily dose creates challenges in dose volume, taste masking, chemical stability, microbial control, and packaging. Granules or dispersible tablets may offer a more practical alternative.

Does Tazverik have biosimilar competition?

No. Tazemetostat is a chemically synthesized small molecule. Competition would arise through generic ANDA products or other branded oncology therapies.

Could a 400 mg Tazverik tablet improve commercial performance?

Potentially. A 400 mg tablet could reduce daily tablet count from eight to four while retaining a manageable unit size. The product would require comparative pharmacokinetic, dissolution, stability, and manufacturing data.

What is the most defensible Tazverik formulation patent?

A patent combining a defined excipient system with a measurable result, such as improved dissolution after storage, rapid disintegration, reduced tablet mass, or enhanced moisture stability, is generally more defensible than a claim covering a conventional excipient substitution alone.

References

1. U.S. Food and Drug Administration. (2024). Tazverik (tazemetostat) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2019). ANDA submissions: Refuse-to-receive standards guidance for industry. FDA.

4. U.S. Food and Drug Administration. (2014). Size, shape, and other physical attributes of generic tablets and capsules: Guidance for industry. FDA.

5. International Council for Harmonisation. (2020). ICH Q3D(R2): Guideline for elemental impurities. ICH.

6. International Council for Harmonisation. (2003). ICH Q8(R2): Pharmaceutical development. ICH.

7. Ipsen. (2024). Universal registration document and annual financial report. Ipsen.

8. Epizyme, Inc. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.